HER2 Targeted Therapies Global Market Report 2026

Description

HER2-targeted therapy is a form of cancer treatment that specifically targets the human epidermal growth factor receptor 2 (HER2), a protein involved in the growth and spread of certain tumors. It is primarily utilized in cancers that are classified as HER2-positive. These therapies function by attaching to the HER2 receptor or blocking its associated signaling mechanisms to inhibit the proliferation of cancer cells. As a component of precision medicine, they often offer improved treatment effectiveness with reduced toxicity compared to conventional chemotherapy.

The primary therapy categories of HER2 targeted therapies include monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates. Monoclonal antibodies are biologic treatments engineered to specifically target HER2 receptors and inhibit the growth of cancer cells. These therapies are used for indications including breast cancer, gastric cancer, and colorectal cancer and are delivered through oral and intravenous administration routes. They are distributed via hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by hospitals, oncology clinics, and cancer specialty centers.

Tariffs are influencing the HER2 targeted therapy market by elevating the cost of imported biologic medicines, antibody drug conjugates, and active pharmaceutical ingredients used in advanced oncology treatment regimens. This is creating affordability pressures on healthcare systems, particularly in import reliant regions such as Asia-Pacific and parts of Latin America. Hospital pharmacies and oncology specialty centers are the most significantly affected segments because of their dependence on high cost biologics and cross border supply chains. However, tariffs are also fostering growth in domestic biologics manufacturing, biosimilar development, and regional pharmaceutical production capabilities, thereby enhancing long term supply chain diversification and improving treatment accessibility.

The HER2 targeted therapies market size has grown strongly in recent years. It will grow from $10.84 billion in 2025 to $11.75 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to rising incidence of breast and gastric cancer cases, increasing uptake of monoclonal antibody treatments such as trastuzumab, expanding awareness of targeted cancer therapy approaches, development of oncology care infrastructure in hospitals, and growing activity in clinical trials focused on HER2-positive cancers.

The HER2 targeted therapies market size is expected to see strong growth in the next few years. It will grow to $16.34 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing adoption of precision oncology and biomarker-based testing, rising development of advanced next-generation antibody drug conjugate (ADC) therapies, broader implementation of personalized cancer treatment protocols, expanding investment inflows into biotechnology and biologics production capabilities, and a growing number of regulatory approvals for targeted oncology therapeutics. Key trends during the forecast period include the widening application of antibody drug conjugates in HER2-positive cancer indications, increasing uptake of biosimilar HER2-targeted treatment options, greater utilization of combination therapies involving chemotherapy and immunotherapy, rapid advancement of next-generation tyrosine kinase inhibitors, and the evolution of biomarker-guided personalized oncology care pathways.

The growing adoption of personalized medicine is expected to propel the growth of the HER2-targeted therapies market going forward. Personalized medicine refers to a medical approach that tailors treatment strategies based on an individual patient's genetic profile, biomarker expression, and specific disease characteristics to improve therapeutic outcomes and minimize adverse effects. The growing adoption of personalized medicine is increasing due to advancements in genomic and biomarker testing, enabling more precise and effective treatments tailored to individual patient profiles while reducing adverse effects. HER2-targeted therapies support personalized medicine adoption by providing highly specific treatment options for patients with HER2-positive cancers, improving treatment effectiveness and enabling more precise disease management. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six approvals in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the HER2-targeted therapies market.

Leading companies operating in the HER2-targeted therapies market are focusing on developing advanced therapies, such as HER2-mutant advanced non-small cell lung cancer targeted therapy, to improve clinical outcomes for patients with HER2-mutant cancers. HER2-mutant advanced non-small cell lung cancer targeted therapy refers to precision treatments that specifically target HER2 gene mutations in advanced NSCLC to improve treatment response and control tumor progression with greater accuracy. For example, in February 2026, Boehringer Ingelheim, a Germany-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for HERNEXEOS (zongertinib), the first targeted therapy approved as an initial treatment option for adults with HER2-mutant advanced non-small cell lung cancer (NSCLC). HERNEXEOS is an orally administered, irreversible HER2-selective tyrosine kinase inhibitor designed to specifically target HER2 (ERBB2) mutations while minimizing wild-type EGFR-related toxicities. The therapy demonstrated a 76% objective response rate in the Beamion LUNG-1 clinical trial and offers once-daily oral administration, improved tolerability, and enhanced precision treatment for patients with unresectable or metastatic HER2-mutant NSCLC.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen, Inc. for an overall enterprise value of approximately $43 billion. Through this acquisition, Pfizer aimed to strengthen its oncology portfolio by integrating Seagen's leading antibody-drug conjugate (ADC) platform and its HER2-targeted ADC therapies, including assets active in both HER2-positive and HER2-low cancers, into Pfizer's global research, development, and commercial infrastructure. Seagen, Inc. is a US-based biotechnology company specializing in antibody-drug conjugate therapies for solid tumors and hematologic cancers, with a core pipeline including HER2-targeted ADC candidates.

Major companies operating in the HER2 targeted therapies market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Novartis AG, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Daiichi Sankyo Company Limited, Celltrion Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Biocon Biopharmaceuticals Pvt. Ltd., Shanghai Henlius Biotech Inc., RemeGen Co. Ltd., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Alteogen Inc., Dizal Pharmaceutical Co. Ltd., Mersana Therapeutics Inc., BioAtla Inc.

North America was the dominant region in the HER2 targeted therapies market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in HER2 targeted therapies report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the HER2 targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The HER2 targeted therapies market consists of sales of margetuximab, tucatinib, neratinib, and pyrotinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The HER2 targeted therapies market research report is one of a series of new reports from The Business Research Company that provides HER2 targeted therapies market statistics, including HER2 targeted therapies industry global market size, regional shares, competitors with a HER2 targeted therapies market share, detailed HER2 targeted therapies market segments, market trends and opportunities, and any further data you may need to thrive in the HER2 targeted therapies industry. This HER2 targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

HER2 Targeted Therapies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses her2 targeted therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for her2 targeted therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The her2 targeted therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Therapy Type: Monoclonal Antibodies; Tyrosine Kinase Inhibitors; Antibody Drug Conjugates
2) By Indication Type: Breast Cancer; Gastric Cancer; Colorectal Cancer
3) By Route Of Administration Type: Oral; Intravenous
4) By Distribution Channel Type: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User Type: Hospitals; Oncology Clinics; Cancer Specialty Centers
Subsegments:
1) By Monoclonal Antibodies: Trastuzumab Based Therapies; Pertuzumab Based Therapies; Margetuximab Based Therapies; Biosimilar Monoclonal Antibodies
2) By Tyrosine Kinase Inhibitors: Lapatinib Based Inhibitors; Neratinib Based Inhibitors; Tucatinib Based Inhibitors; Afatinib Based Inhibitors
3) By Antibody Drug Conjugates: Trastuzumab Emtansine; Trastuzumab Deruxtecan; Next Generation Human Epidermal Growth Factor Receptor Two Antibody Drug Conjugates
Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; AstraZeneca PLC; Novartis AG; Gilead Sciences Inc.; Amgen Inc.; Boehringer Ingelheim International GmbH; Viatris Inc.; Daiichi Sankyo Company Limited; Celltrion Inc.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Biocon Biopharmaceuticals Pvt. Ltd.; Shanghai Henlius Biotech Inc.; RemeGen Co. Ltd.; Zymeworks Inc.; Puma Biotechnology Inc.; MacroGenics Inc.; Alteogen Inc.; Dizal Pharmaceutical Co. Ltd.; Mersana Therapeutics Inc.; BioAtla Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH3MHTTA01_G26Q2

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. HER2 Targeted Therapies Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global HER2 Targeted Therapies Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. HER2 Targeted Therapies Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global HER2 Targeted Therapies Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Internet Of Things (IoT), Smart Infrastructure & Connected Ecosystems
- 4.1.5 Industry 4.0 & Intelligent Manufacturing
4.2. Major Trends
- 4.2.1 Expansion Of Antibody Drug Conjugates In HER2 Positive Cancers
- 4.2.2 Increasing Adoption Of Biosimilar HER2 Targeted Therapies
- 4.2.3 Rising Use Of Combination Regimens With Chemotherapy And Immunotherapy
- 4.2.4 Growth In Next Generation Tyrosine Kinase Inhibitors
- 4.2.5 Development Of Biomarker Driven Personalized Oncology Treatment Pathways

5. HER2 Targeted Therapies Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Oncology Clinics
5.3 Cancer Specialty Centers
5.4 Research Institutes
5.5 Other End Users

6. HER2 Targeted Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global HER2 Targeted Therapies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global HER2 Targeted Therapies PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global HER2 Targeted Therapies Market Size, Comparisons And Growth Rate Analysis
7.3. Global HER2 Targeted Therapies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global HER2 Targeted Therapies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global HER2 Targeted Therapies Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. HER2 Targeted Therapies Market Segmentation

9.1. Global HER2 Targeted Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Antibody Drug Conjugates
9.2. Global HER2 Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Breast Cancer, Gastric Cancer, Colorectal Cancer
9.3. Global HER2 Targeted Therapies Market, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Intravenous
9.4. Global HER2 Targeted Therapies Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
9.5. Global HER2 Targeted Therapies Market, Segmentation By End User Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Oncology Clinics, Cancer Specialty Centers
9.6. Global HER2 Targeted Therapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Trastuzumab Based Therapies, Pertuzumab Based Therapies, Margetuximab Based Therapies, Biosimilar Monoclonal Antibodies
9.7. Global HER2 Targeted Therapies Market, Sub-Segmentation Of Tyrosine Kinase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Lapatinib Based Inhibitors, Neratinib Based Inhibitors, Tucatinib Based Inhibitors, Afatinib Based Inhibitors
9.8. Global HER2 Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Trastuzumab Emtansine, Trastuzumab Deruxtecan, Next Generation Human Epidermal Growth Factor Receptor Two Antibody Drug Conjugates

10. HER2 Targeted Therapies Market Regional And Country Analysis

10.1. Global HER2 Targeted Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global HER2 Targeted Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific HER2 Targeted Therapies Market

11.1. Asia-Pacific HER2 Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China HER2 Targeted Therapies Market

12.1. China HER2 Targeted Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India HER2 Targeted Therapies Market

13.1. India HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan HER2 Targeted Therapies Market

14.1. Japan HER2 Targeted Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia HER2 Targeted Therapies Market

15.1. Australia HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia HER2 Targeted Therapies Market

16.1. Indonesia HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea HER2 Targeted Therapies Market

17.1. South Korea HER2 Targeted Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan HER2 Targeted Therapies Market

18.1. Taiwan HER2 Targeted Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia HER2 Targeted Therapies Market

19.1. South East Asia HER2 Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe HER2 Targeted Therapies Market

20.1. Western Europe HER2 Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK HER2 Targeted Therapies Market

21.1. UK HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany HER2 Targeted Therapies Market

22.1. Germany HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France HER2 Targeted Therapies Market

23.1. France HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy HER2 Targeted Therapies Market

24.1. Italy HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain HER2 Targeted Therapies Market

25.1. Spain HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe HER2 Targeted Therapies Market

26.1. Eastern Europe HER2 Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia HER2 Targeted Therapies Market

27.1. Russia HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America HER2 Targeted Therapies Market

28.1. North America HER2 Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA HER2 Targeted Therapies Market

29.1. USA HER2 Targeted Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada HER2 Targeted Therapies Market

30.1. Canada HER2 Targeted Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America HER2 Targeted Therapies Market

31.1. South America HER2 Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil HER2 Targeted Therapies Market

32.1. Brazil HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East HER2 Targeted Therapies Market

33.1. Middle East HER2 Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa HER2 Targeted Therapies Market

34.1. Africa HER2 Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa HER2 Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication Type, Segmentation By Route Of Administration Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. HER2 Targeted Therapies Market Regulatory and Investment Landscape

36. HER2 Targeted Therapies Market Competitive Landscape And Company Profiles

36.1. HER2 Targeted Therapies Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. HER2 Targeted Therapies Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. HER2 Targeted Therapies Market Company Profiles
- 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. HER2 Targeted Therapies Market Other Major And Innovative Companies

Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Daiichi Sankyo Company Limited, Celltrion Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Biocon Biopharmaceuticals Pvt. Ltd., Shanghai Henlius Biotech Inc., RemeGen Co. Ltd., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Alteogen Inc., Dizal Pharmaceutical Co. Ltd., Mersana Therapeutics Inc., BioAtla Inc.

38. Global HER2 Targeted Therapies Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The HER2 Targeted Therapies Market

41. HER2 Targeted Therapies Market High Potential Countries, Segments and Strategies

41.1 HER2 Targeted Therapies Market In 2030 - Countries Offering Most New Opportunities
41.2 HER2 Targeted Therapies Market In 2030 - Segments Offering Most New Opportunities
41.3 HER2 Targeted Therapies Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations
42.2. Currencies
42.3. Historic And Forecast Inflation Rates
42.4. Research Inquiries
42.5. The Business Research Company
42.6. Copyright And Disclaimer